Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma

Clinical Nuclear Medicine

Volumn 34, Issue 12, 2009, Pages 874-877

  Huo, Li ^a   Wu, Zhanhong ^a   Zhuang, Hongming ^a,b   Fu, Zhe ^a   Dang, Yonghong ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

C 11 acetate; Focal nodular hyperplasia; Hepatocellular carcinoma; Positron emission tomography

Indexed keywords

ACETIC ACID C 11; FLUORODEOXYGLUCOSE;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; LIVER CELL CARCINOMA; MALE; NODULAR HYPERPLASIA; POSITRON EMISSION TOMOGRAPHY;

ACETATES; CARBON; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEASIBILITY STUDIES; FOCAL NODULAR HYPERPLASIA; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 74249091907     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181bed06e     Document Type: Article

References (41)

1. Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4:252-261.
2. Gomaa AI, Khan SA, Leen EL, et al. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009;15:1301-1314.
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
4. Vilgrain V. Focal nodular hyperplasia. Eur J Radiol. 2006;58:236-245.
5. Laurent C, Trillaud H, Lepreux S, et al. Association of adenoma and focal nodular hyperplasia: experience of a single French academic center. Comp Hepatology. 2003;2:10.
6. Lee YH, Kim SH, Cho MY, et al. Focal nodular hyperplasia-like nodules in alcoholic liver cirrhosis: radiologic-pathologic correlation. Am J Roentgenol. 2007;188:W459-W463.
7. Sotiropoulos GC, Bockhorn M, Molmenti EP, et al. Hepatocellular carcinoma as a coincidental finding in a patient undergoing surgery for focal nodular hyperplasia. Liver Int. 2008;28:578-579.
8. Hanna RF, Aguirre DA, Kased N, et al. Cirrhosis-associated hepatocellular nodules: Correlation of histopathologic and MR imaging features. Radiographics. 2008;28:747-769.
9. Kawaoka T, Aikata H, Takaki S, et al. FDG positron emission tomography/ computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res. 2009;39:134-142.
10. Mocherla B, Kim J, Roayaie S, et al. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med. 2007;32: 947-948.
11. Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004;39:961-968.
12. Zhuang H, Sinha P, Pourdehnad M, et al. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nucl Med Commun. 2000;21:793-798.
13. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: Comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med. 2004;45: 1892-1897.
14. Anderson GS, Brinkmann F, Soulen MC, et al. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med. 2003;28:192-197.
15. Hwang KH, Choi DJ, Lee SY, et al. Evaluation of patients with hepatocellular carcinomas using [(11)C]acetate and [(18)F]FDG PET/CT: A preliminary study. Appl Radiat Isot. 2009;67:1195-1198.
16. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32: 792-797.
17. Verhoef C, Valkema R, de Man RA, et al. Fluorine-18 FDG imaging in hepatocellular carcinoma using positron coincidence detection and single photon emission computed tomography. Liver. 2002;22:51-56.
18. Salem N, Kuang Y, Wang F, et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2-(18)F-fluoro-D-glucose, 6-deoxy-6-(18)F-fluoro-D-glucose,-(1-11) C-acetate and-N-methyl-(11)C-choline. Q J Nucl Med Mol Imaging. 2008;53:144-156.
19. Paudyal B, Oriuchi N, Paudyal P, et al. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med. 2008;22:3.
20. Kurtaran A, Becherer A, Pfeffel F, et al. 18F-Fluorodeoxyglucose (FDG)- PET features of focal nodular hyperplasia (FNH) of the liver. Liver. 2000; 20:3.
21. Ho CL Yu SC, Yeung WC. C-11 Acetate PET Imaging in Hepatocellular Carcinoma and Other Liver Masses. J Nucl Med. 2003;44:8.
22. Park JW, Kim JH, Kim SK, et al. A prospective evaluation of F-18FDG and C-11 acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:8.
23. Huo L, Chou C, Dang YH, et al. Combination of C-11-Acetate and F-18-DG PET for the diagnosis of hepatic neoplasms. J Nucl Med. 2007;48(suppl 2):1.
24. Ho CL, Chen S, Yeung DW, et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med. 2007;48:902-909.
25. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med. 1998;39:1302-1305.
26. Ho CL, Yu S, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213-221.
27. Kotzerke J, Volkmer BG, Glatting G, et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 2003;42:25-30.
28. Tsuchida T, Takeuchi H, Okazawa H, et al. Grading of brain glioma with 1-11C-acetate PET: Comparison with 18F-FDG PET. Nucl Med Biol. 2008; 35:171-176.
29. Hussain K, El-Serag HB. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2009;55:123-138.
30. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97-104.
31. Procacci C, Fugazzola C, Cinquino M, et al. Contribution of CT to characterization of focal nodular hyperplasia of the liver. Gastrointest Radiol. 1992;17:63-73.
32. Lee J, Lee WJ, Lim HK, et al. Early hepatocellular carcinoma: Three-phase helical CT features of 16 patients. Korean J Radiol. 2008;9:325-332.
33. Sahlmann CO, Siefker U, Lehmann K, et al. Dual time point 2-[18F]fluoro- 2-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun. 2004;25:819-823.
34. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-d- glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651-3658.
35. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
36. Tian R, Su M, Tian Y, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol. 2009; 38:451-458.
37. Xiu Y, Bhutani C, Dhurairaj T, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32:101-105.
38. Shinya T, Rai K, Okumura Y, et al. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer. Clin Nucl Med. 2009;34:216-221.
39. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633-638.
40. Arena V, Skanjeti A, Casoni R, et al. Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake. Radiol Med. 2008;113: 875-886.
41. Zytoon AA, Murakami K, El-Kholy MR, et al. Positron emission tomography and breast lesions: low FDG activity in early phase imaging is not essentially benign. Clin Nucl Med. 2008;33:931-933.